New drug combo shows promise in Hard-to-Treat cancers
NCT ID NCT05763004
First seen Apr 10, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This early-phase trial tests a new drug called IOS-1002, given alone or with pembrolizumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 140 participants will take part in three study parts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfread Health
Melbourne, Australia
-
Austin Health / Cancer Clinical Trials Center
Heidelberg, Australia
-
Linear Clinical Research
Perth, Australia
-
Monash Health Medical Center
Clayton, Australia
-
Peter MacCallum Cancer Center
Melbourne, Australia
Conditions
Explore the condition pages connected to this study.